查詢結果分析
來源資料
相關文獻
- Effect of Silymarin on Hepatic Function of Patients with Unresectable Hepatocellular Carcinoma after Transcatheter Hepatic Arterial Chemoembolization
- Successful Treatment of a Bulky Seminoma in an Abdominal Undescended Testis: A Case Report
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- Hemoperitoneum Secondary to Biopsy of the Hepatic Angiosarcoma
- The Experience of Combination of Chemotherapy and Surgery in Treatment of Advanced Nonseminomatous Germ Cell Tumor of the Testis
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- 非小細胞肺癌術前輔助性化學治療的經驗
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Nausea and Vomiting of Cancer Chemotherapy
頁籤選單縮合
題 名 | Effect of Silymarin on Hepatic Function of Patients with Unresectable Hepatocellular Carcinoma after Transcatheter Hepatic Arterial Chemoembolization=Silymarin對於罹患無法切除之肝腫瘤病人在進行經肝動脈栓塞合併化學治療後之肝功能的影響 |
---|---|
作 者 | 李志明; 梁庭繼; 張君照; 郭于誠; 邱仲峰; 王鴻蓉; 陳雅妍; | 書刊名 | 中華放射線醫學雜誌 |
卷 期 | 33:3 2008.09[民97.09] |
頁 次 | 頁137-141 |
分類號 | 416.246 |
關鍵詞 | 肝腫瘤; 肝動脈栓塞; 化學治療; |
語 文 | 英文(English) |
中文摘要 | 經肝動脈栓塞合併化學治療是治療無法切除之肝腫瘤常用的方法。Silymarin是水飛薊植物的衍生物,它被廣泛地使用在慢性肝疾病上。在台灣,有一些醫師會建議病患在進行經肝動脈栓塞合併化學治療後,服用silymarin來作為保肝劑。本研究探討silymarin在此模式下之有效性。 本研究共有244位接受經肝動脈栓塞合併化學治療之病患,這些病患在術前之Child-Pugh classification皆無顯著差異。其中111位在經肝動脈栓塞合併化學治療後,每日服用280毫克的silymarin持續兩週,另外133位在治療後不服用silymarin。紀錄病患術前、術後第二、四、六天及二、三、四、五週之肝功能相關數據。 結果顯示,兩組病患之肝功能(包括ALT、AST、鹼性磷酸、總膽紅素、白蛋白、乳糖脫氫酶)在各個不同的時間點時,皆無顯著差異。 每日服用280毫克的silymarin持續兩週,並不能顯著改善經肝動脈栓塞合併化學治療後病患之肝功能,顯示silymarin投與之劑量及時間長短須經更嚴密的設計。 |
英文摘要 | Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting. |
本系統中英文摘要資訊取自各篇刊載內容。